C. Steendam

Improving the tolerability of osimertinib by identifying its toxic limit

Bram C. Agema, G. Veerman, C. Steendam et al. · Therapeutic Advances in Medical Oncology · 2022 · 41 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer

C. Steendam, G. Veerman, Melinda A. Pruis et al. · Cancers · 2020 · 20 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study

C. Steendam, Sophie M. Ernst, Sushil K. Badrising et al. · Lung Cancer · 2023 · 18 citations · Full text

Medicine, Oncology, Pharmacology +16

Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients

G. Veerman, Koen G. A. M. Hussaarts, Robert Peric et al. · Clinical Pharmacokinetics · 2020 · 13 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with <i>EGFR</i> mutated non‐small cell lung cancer

Ard van Veelen, G. Veerman, Marjon V. Verschueren et al. · International Journal of Cancer · 2023 · 13 citations · Full text

Medicine, Oncology, Pharmacology +16